Auriga, Balchem to develop rapid dissolve drug formulas

By Elaine Rigoli

Tampa, Fla., Aug. 8 - Auriga Laboratories, Inc. announced the execution of a development agreement with Balchem Corp. to develop a set of novel combination medicines in the rapid dissolve format.

Under the agreement, Balchem will provide Pharmashure taste-masking technology for Auriga to use in its prescription pain products. Two product candidates have been identified for development.

"We recognized and seized a unique opportunity to use this innovative and cost-effective taste-masking technology in the development of new and proprietary rapid-dissolve formulations for our prescription pain products, and subsequently for our respiratory franchise. We believe Balchem's superior encapsulation technology will have substantial market advantages which will lead to the benefit of improved patient compliance and support the acceleration of our drug product sales and growth," Auriga chief executive officer Philip Pesin said in a news release.

Based in New Hampton, N.Y., Balchem provides solutions and products for a range of industries worldwide.

Auriga is a specialty pharmaceutical company and is located in Norcross, Ga.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.